Table 2.
Chronologic presentation of studies on naturally occurring OA applying allogeneic MSC.
| Author | # Patients | Groups/treatment | OA location | MSC source | Injection site | Dosage MSC (cells) | # Injections | Outcome | Side effects MSCs |
|---|---|---|---|---|---|---|---|---|---|
| Marx et al., (40) | 9 | MSC: 5Stromal vascular fraction (SVF): 4 | hip | fat | 3 acupuncture points | 0.2–0.8 × 106 | 1 | + | No |
| Bootcha et al., (60) | 8 | MSC: 8 | hip | Dental pulp | IA | 5 × 106 | Multipe (not specified) | + | No |
| Harman et al., (38) | 74 | MSC: 38Control: 36 | Different joints | fat | IA | 12 × 106 | 1 | + | No |
| Kriston-Pal et al., (39) | 30 (39 elbows) | MSC + HA: 30 | elbow | fat | IA | 12 × 106 ± 3.2 × 106 | 1 | + | Yes (2 of 39 joints) |
| Shah et al., (44) | 203 | MSC IA: 128MSC IV: 65MSC IA + IV: 10 | Different joints | fat | IA and/or IV | Not specified | 1 | IA/IA+IV: 90% +IV: 76% + | Yes (2 dogs) |
| Cabon et al., (61) | 22 | MSC: 22Repeated treatment (RT): 8 | Different joints | Fetal adnexa | IA | ≥ 10 × 106 | 1 2 (8 dogs) | + | MSC: 5 <48u RT: 4 <48u |
| Kim et al., (62) | 68 | MSC: 38Control: 30 | elbow | Umbilical cord | IA | 7 × 106 | 1 | + | No |
| Olson et al., (43) | 13 | MSC: 13 | elbow | fat | IV | 1–2 × 106/kg body weight | 3 | + (subjective)= (objective) | No |
| Wits et al., (49) | 12 (24 hips) | MSC: 4MSC + HA: 4Control: 4 | hip | fat | IA | 5 × 106 | 1 | = | No |